The Memo: NIMBLE Diagnostics Bringing Visibility to Vascular Implants

Under the direction of Co-Founder and CEO Dr. Oriol Iborra Egea, NIMBLE Diagnostics is creating a new frontier in implant monitoring and vascular care. With a non-invasive, microwave-based diagnostic device designed to monitor implanted stents in real time, NIMBLE is solving a long-standing blind spot in cardiovascular care: knowing what’s happening inside a stent without having to go back inside the body.

“We implant a stent, we send the patient home, and we assume everything’s fine — until it’s not,” said Iborra. “We’ve built a way to monitor that stent non-invasively, quickly, and safely — before a serious event occurs.”

From a research project in Barcelona to a fast-moving medtech startup with international ambitions, NIMBLE Diagnostics is on a mission to redefine how clinicians follow up with patients after stent implantation — and to prevent life-threatening complications before they happen.

Origin Story

NIMBLE Diagnostics was born from a collaborative research effort among several investigators from the Germans Trias i Pujol Hospital and affiliated universities. From this joint initiative, cardiovascular researcher Dr. Oriol Iborra Egea and telecommunications engineer Susana Amorós took the lead and spearheaded the creation of the startup to make the technology a clinical reality. The two first crossed paths at a public hospital in Barcelona, where they collaborated on early research to improve stent monitoring technologies. Combining Iborra’s background in translational cardiovascular science with Amorós’s engineering expertise, they set out to solve a critical clinical challenge: how to monitor stent performance non-invasively and in real time.

Their early concept — using microwave signals to assess stent integrity and patency — showed promise in simulations and in vitro studies. However, initial animal trials with a probe-based design were unsuccessful due to limited tissue penetration. That challenge led to a key breakthrough: replacing the probes with external antennas. Amorós played a central role in refining this technical pivot, which dramatically improved the system’s performance and opened the door to clinical feasibility.

Encouraged by the results and united by a mission to improve patient care, Iborra and Amorós co-founded NIMBLE Diagnostics in March 2022. Together with a multidisciplinary team, they’re translating a promising research concept into a clinically impactful solution.


This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-memo-nimble-diagnostics-bringing-visibility-to-vascular-implants 

Comments

Post a Comment

Popular posts from this blog

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more

Q1 2025 Medical Device Investment Roundup: A Record-Breaking Start to a Year of Reckoning

Big deals, even bigger questions. Jonathan Norris of HSBC Innovation Banking explains why 2025 is already one for the books. Venture investment across the medical device sector kicked off 2025 with a bang, posting $2.6 billion in first-quarter funding across 132 deals — the highest quarterly dollar mark in three years. According to  Jonathan Norris , Managing Director at  HSBC Innovation Banking , who writes comprehensive reports on the venture healthcare ecosystem, this surge marks a 20% rise in both capital and deal count compared to the 2024 average. “Not only did we have more dollars, but there were more deals, which is really good to see,” Norris says, in a recent interview with  The Lens . “I think the quick and easy takeaway is that more companies were getting funded in Q1, and a good percentage of the bigger deals in the quarter were PMA pivotal trial rounds. It looks like positive momentum for the sector to see a big quarter. That’s our 35,000-foot view.” But ben...
Read more